Cabotegravir with rilpivirine for treating HIV-1 (TA757)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 January 2022
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TS ID 10723]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenacapavir for treating multidrug resistant HIV-1 ID6196Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC